- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04251819
Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers
December 20, 2023 updated by: Karen Cropsey, University of Alabama at Birmingham
To determine if baclofen will enhance buprenorphine analgesia for acute pain in healthy volunteers.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Abuse of opioids is a significant and growing problem in the United States.
In the past two decades, opioid prescriptions have quadrupled while the age of heroin initiation has decreased, suggesting that more individuals are using opioids and transitioning to heroin and potent synthetic opioids than in the past.
Further, fatal opioid overdose is now the leading cause of accidental death and is the 5th highest overall cause of mortality in the US.
Engaging opioid users in opioid agonist treatments has been shown to lower rates of criminal behavior, lower rates of non-opioid drug use, and increase retention in drug treatment programs, while decreasing mortality and new HIV and hepatitis infections.
However, a recent study noted that 68% of patients prescribed buprenorphine had poor medication adherence, which was associated with illicit opioid use.
A Cochrane review concluded that buprenorphine was less effective at retaining patients in treatment relative to methadone.
One reason for lower treatment retention may be the high comorbidity of opioid use disorder and chronic pain and/or opioid-induced hyperalgesia.
Buprenorphine, as a partial mu agonist, provides lower analgesia but an improved safety profile relative to full agonists like methadone.
Thus, enhancing the analgesic properties of buprenorphine will provide a safer alternative for opioid use disorder patients with chronic pain/hyperalgesia.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Karen L Cropsey, Psy.D.
- Phone Number: 2059754204
- Email: kcropsey@uab.edu
Study Contact Backup
- Name: Keith Chichester, B.A.
- Phone Number: 2059757809
- Email: krc80@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- University of Alabama, Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18 years or older
- general good health
- English speaking
Exclusion Criteria:
- Pregnant or nursing
- Opioid use disorder or any substance use disorder other than nicotine
- Prescribed agonist treatment for opioid dependence or prescribed opioids for a medical condition
- Prescribed naltrexone
- Known sensitivity to buprenorphine, naloxone, or baclofen
- Acute or chronic pain condition
- Trouble breathing or a pulmonary condition
- Prescribed benzodiazepines or daily use of benzodiazepines
- Positive drug screen (positive cannabis result allowed)
- Cognitive impairment or psychiatric disorder requiring treatment
- Uncontrolled hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants randomized to this arm will receive Placebo.
|
Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Experimental: Baclofen 5mg
Participants randomized to this arm will receive 5 mg of Baclofen.
|
Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Experimental: Baclofen 10mg
Participants randomized to this arm will receive 10 mg of Baclofen.
|
Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Threshold
Time Frame: Baseline
|
Pain threshold refers to the intensity at which a stimulus is first perceived as painful.
Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe.
From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device.
For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline
|
Pain Threshold
Time Frame: Baseline through one week
|
Pain threshold refers to the intensity at which a stimulus is first perceived as painful.
Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe.
From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device.
For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline through one week
|
Pain tolerance
Time Frame: Baseline
|
Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate.
Heat stimuli will again be delivered using the computer-controlled thermal stimulation system.
From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device.
For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline
|
Pain tolerance
Time Frame: Baseline through one week
|
Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate.
Heat stimuli will again be delivered using the computer-controlled thermal stimulation system.
From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device.
For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline through one week
|
Temporal summation of pain
Time Frame: Baseline
|
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input.
Temporal summation is presumed to be the psychophysical manifestation of wind-up.
Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline
|
Temporal summation of pain
Time Frame: Baseline through one week
|
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input.
Temporal summation is presumed to be the psychophysical manifestation of wind-up.
Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline through one week
|
Conditioned pain modulation
Time Frame: Baseline
|
A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus).
Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline
|
Conditioned pain modulation
Time Frame: Baseline through one week
|
A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus).
Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn.
Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
|
Baseline through one week
|
Suprathreshold pain response
Time Frame: Baseline
|
Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable
|
Baseline
|
Suprathreshold pain response
Time Frame: Baseline through one week
|
Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable
|
Baseline through one week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid Symptom Checklist
Time Frame: One to seven days post baseline
|
Lists True-False questions measuring opioid effects.
|
One to seven days post baseline
|
McGill Pain Questionnaire-Short Form
Time Frame: One to seven days post baseline
|
15 descriptors (11 sensory; 4 affective) using an intensity scaled ranging from 0-3 on pain.
0 being the least amount of pain and 3 being the most amount of pain.
|
One to seven days post baseline
|
26-item Visual Analog Scale (VAS)
Time Frame: One to seven days post baseline
|
Measures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication.
|
One to seven days post baseline
|
Drug Effects Questionnaire-5
Time Frame: One to seven days post baseline
|
Assesses drug effects and uses VAS ratings from "Not at all" to "Very much."
|
One to seven days post baseline
|
26-item Visual Analog Scale ("Subjective drug effects")
Time Frame: One to seven days post baseline
|
This 26-item VAS measures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication.
|
One to seven days post baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Karen L Cropsey, Psy.D., University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 21, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
December 18, 2019
First Submitted That Met QC Criteria
January 29, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Estimated)
December 21, 2023
Last Update Submitted That Met QC Criteria
December 20, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 300004505
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia
-
Mansoura UniversityNot yet recruiting
-
Southeast University, ChinaRecruiting
-
Medical University of South CarolinaRecruiting
-
Southeast University, ChinaRecruiting
-
Huazhong University of Science and TechnologyRecruiting
-
Mansoura UniversityCompleted
-
University of FloridaMdoloris Medical SystemsCompletedAnalgesiaUnited States
-
Mansoura UniversityCompleted
-
Cessatech A/SCompleted
-
Kalyra Pharmaceuticals, Inc.United States Department of Defense; PRA Health SciencesTerminated
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France